Allogene astounds Wall Street with $324m IPO to fund cell therapy R&DGreat things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun Share XAllogene astounds Wall Street with $324m IPO to fund cell therapy R&Dhttps://pharmaphorum.com/news/allogene-astounds-wall-street-with-324m-ipo-to-fund-cell-therapy-rd/
Sandoz free to launch Humira biosimilar following AbbVie dealNovartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) Share XSandoz free to launch Humira biosimilar following AbbVie dealhttps://pharmaphorum.com/news/sandoz-free-to-launch-humira-biosimilar-following-abbvie-deal/
EU regulators review Janssen’s esketamine nasal spray antidepressantAn application for Janssen’s investigative nasal ketamine-based antidepressant is under review in Europe. Janssen, which is Johnson & Share XEU regulators review Janssen’s esketamine nasal spray antidepressanthttps://pharmaphorum.com/news/eu-regulators-review-janssens-esketamine-nasal-spray-antidepressant/
Pfizer appoints chief digital officer in boardroom shakeupPfizer has appointed a chief digital officer because of the growing importance of digital technology in R&D and Share XPfizer appoints chief digital officer in boardroom shakeuphttps://pharmaphorum.com/news/pfizer-appoints-chief-digital-officer-in-boardroom-shakeup/
UK drugs regulator consults on ‘no deal’ Brexit arrangementsDespite the government insisting that Brexit will have no negative fallout, the UK’s drugs regulator is consulting on Share XUK drugs regulator consults on ‘no deal’ Brexit arrangementshttps://pharmaphorum.com/news/uk-drugs-regulator-consults-on-no-deal-brexit-arrangements/
Sandoz encourages digital health innovation in second competitionSandoz has announced a second competition inviting entrepreneurs and innovators in digital health to submit ideas that could Share XSandoz encourages digital health innovation in second competitionhttps://pharmaphorum.com/news/sandoz-encourages-digital-health-innovation-in-second-competition/
Janssen and Arrowhead strike $3.7bn RNAi dealJanssen has struck a deal with Arrowhead Pharmaceuticals to develop an RNA interference drug to treat hepatitis B Share XJanssen and Arrowhead strike $3.7bn RNAi dealhttps://pharmaphorum.com/news/janssen-and-arrowhead-strike-3-7bn-rnai-deal/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
Gilead signs biotech deal arming T-cells to attack solid tumoursGilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors Share XGilead signs biotech deal arming T-cells to attack solid tumourshttps://pharmaphorum.com/news/gilead-signs-biotech-deal-arming-t-cells-to-attack-solid-tumours/
